MACE: Death, MI or TLR at 5 years

Slides:

Advertisements

Similar presentations

Www. Clinical trial results.org The C-SIRIUS Study A The Canadian Multi-Center, Randomized, Double-Blind Study of the Sirolimus-Eluting Stent in the Treatment.

Advertisements

Paclitaxel-eluting Stents vs Brachytherapy for In-stent Restenosis (TAXUS V ISR) Trial Presented at The American College of Cardiology Scientific Session.

“Real World”: SVG, De Novo or Restenotic Coronary Artery Lesions Chronic Stable Angina, Silent Ischemia, Acute Coronary Syndromes Vessel Diameters:

Www. Clinical trial results.org  Major Endpoints: Death, MI, stent thrombosis, TLR, TVR, MACE, and CKMB >3x nl  Major Endpoints: Death, MI, stent thrombosis,

Www. Clinical trial results.org The RAVEL Study A RAndomised (double blind) study with the Sirolimus coated BX™ VElocity balloon expandable stent (CYPHER™)

Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE) Trial Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE)

Trials of radiation to prevent or reduce in-stent restenosis Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director.

The Stent of Choice in ACS patients The Stent of Choice in ACS 1) The Rationale…

Richard Melsheimer Director, Medical Affairs Europe Centocor Eli Lilly and Company Coordinated Use of ReoPro and Drug Eluting Stents: Rationale and Evidence.

Two-Year Clinical Outcomes Yan Li MD., PhD. On behalf of FIREMAN Investigators Associated Professor of Department of Cardiology of Xijing Hospital Fourth.

The REALITY Study Results. REALITY Study Design The REALITY Study : Prospective randomized clinical trial to evaluate the safety and efficacy of CYPHER®

Upendra Kaul, MD for the TUXEDO INDIA Investigators Paclitaxel Eluting Versus Everolimus Eluting Stents in Patients with Diabetes Mellitus and Coronary.

Maurizio Menichelli MD San Camillo Hospital, Rome ( SESAMI Trial) Maurizio Menichelli Presenter Disclosure Information Nothing to Disclose Randomized trial.

SIROLIMUS-ELUTING STENTS EFFECTIVELY INHIBIT NEOINTIMAL PROLIFERATION AS COMPARED TO BARE METAL STENTS IN DISEASED SAPHENOUS VEIN GRAFTS: 6-month IVUS.

Upendra Kaul, MD for the TUXEDO INDIA Investigators Paclitaxel Eluting Versus Everolimus Eluting Stents in Patients with Diabetes Mellitus and Coronary.

Slow-rate release polymer-based paclitaxel- eluting stent compared with bare stent in patients with single complex coronary lesions TAXUS V Presented at.

A Prospective, Randomized Trial Evaluating a Paclitaxel-Eluting Balloon in Patients TReated with Endothelial Progenitor Cell CapTuring Stents for De Novo.

RESOLUTE US One-Year Clinical Outcomes from the Pivotal Multicenter RESOLUTE US Study Objective To evaluate the clinical effectiveness of the Resolute.

Endeavor 4: A Randomized Comparison of a Zotarolimus- Eluting Stent and a Paclitaxel- Eluting Stent in Patients with Coronary Artery Disease Martin B.

Www. Clinical trial results.org Cypher sirolimus-eluting stent Primary Endpoint:  In-stent and late lumen loss at 9 months (determined by QCA) Secondary.

TLR Funnel plot (according to outcomes) for studies included in the meta-analysis Death A TVR B MACE DC SE(log OR)

Is there any role for intravascular ultrasound in bifurcation lesions? Giuseppe Biondi-Zoccai, MD University of Turin, Turin, Italy.

RAVEL 4 YEAR FOLLOW-UP - Cordis Cardiology / Cardialysis – Euro-PCR – Sousa – 24 May 2005 RAVEL A RAndomised, double-blind study with the Sirolimus-eluting.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Randomized Trial of Paclitaxel- Versus Sirolimus-Eluting.

Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at The American College.

Volume 54, Issue 1, Pages (August 2009)

For the HORIZONS-AMI Investigators

ABSORB Japan: 3-year Clinical and Angiographic Results of a Randomized trial Evaluating the Absorb Bioresorbable Vascular Scaffold vs. Metallic Drug-eluting.

LONG-DES II Trial Randomized Comparison of the Efficacy of Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent in the Treatment of Long Native Coronary.

TAXUS IV Trial Slow-rate release polymer-based paclitaxel-eluting stent compared with bare stent in patients with single de novo coronary lesions Presented.

Stenting of Coronary Arteries in Non Stress/Benestent Disease

EMPHASIS-HF Extended Follow-up

SIRIUS Trial: Diameter Restenosis

Two-Year Extended Follow-up in Patients Receiving a Zotarolimus-eluting Stent in the E-Five Registry Martin T. Rothman, Ian T. Meredith, Keyur Parikh,

TAXUS II and IV: two-year follow-up

SKS Technique Clinical Case

Terms of Use. Terms of Use.

American College of Cardiology Presented by Dr. Stephan Windecker

Late Breaking Clinical Trials

FAIR Trial design: Patients with SFA in-stent restenosis (ISR) were randomized to either a paclitaxel-coated balloon (DCB) (dose 3.5 μg/mm2) or routine.

REALITY: 8 month results

EXCITE ISR Trial design: Participants with femoropopliteal in-stent restenosis were randomized to excimer laser atherectomy + adjunctive angioplasty (n.

SMILE Trial design: NSTEMI patients were randomized to complete revascularization during the index procedure (i.e., 1-stage revascularization; n = 264)

TUXEDO–India Trial design: Patients with type 2 diabetes mellitus (DM2) and coronary artery disease undergoing PCI were randomized to receive Taxus Element.

ENDEAVOR IV: 5 Year Final Outcomes

For the HORIZONS-AMI Investigators

Presented at ACC 2003 Late Breaking Clinical Trials

Randomized Comparison in the Setting of Acute MI

ZEUS Trial design: Patients who were deemed uncertain DES candidates due to bleeding, thrombotic, or restenosis risk were randomized to receive either.

SIRIUS: A U.S. Multicenter, Randomized, Double-Blind Study of the SIRolImUS-Eluting Stent in De Novo Native Coronary Lesions Presented at TCT 2002.

American Heart Association Presented by Dr. Julinda Mehilli

Main branch restenosis at 1 year

Drug-eluting stents for in-stent restenosis

ENDEAVOR II Five-Year Clinical Follow-up

Role of Stenting in Acute MI: PAMI Stent Pilot Trial

Translation Pathway for Coronary Stent Development- Clinical Endpoints

SMART-STRATEGY Trial design: Patients with a bifurcation coronary lesion were randomized to a conservative strategy (n = 128) vs. an aggressive strategy.

ENDEAVOR III Multicenter Randomized Trial Clinical/MACE Angio/IVUS

ORAL CILOSTAZOL TREATMENT PREVENTS RESTENOSIS AND MAJOR ADVERSE CLINICAL EVENTS AFTER DRUG-ELUTING STENT IMPLANTATION: EVIDENCE FROM A META-ANALYSIS G.

Updated 3-Year Meta-Analysis of the TAXUS Clinical Trials Safety and Efficacy Demonstrated in 3,445 Randomized Patients Time allocation for this talk.

Martin B. Leon, David R. Holmes, Dean J. Kereiakes, Jeffrey J

Maintenance of Long-Term Clinical Benefit with

Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions Osamu Iida, MD, Shinsuke Nanto, MD, Masaaki Uematsu,

Comparison of Everolimus-Eluting and Paclitaxel-Eluting Stents: First Report of the Five-Year Clinical Outcomes from.

DANAMI 3-DEFER Trial design: Patients presenting with STEMI and in whom the operators could establish TIMI 2-3 flow without stenting or those presenting.

Primary safety endpoint

Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial

IVUS-XPL Trial design: Patients undergoing drug-eluting stent implantation for long coronary lesions were randomized to IVUS-guided PCI (n = 700) vs. angiography-guided.

American College of Cardiology Presented by Dr. Adnan Kastrati

TYPHOON Trial Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at.

Presentation transcript:

MACE: Death, MI or TLR at 5 years Gamma-1: Five Year Follow-up Vascular Gamma Brachytherapy vs placebo for In-stent Restenosis in Native Coronary Lesions MACE: Death, MI or TLR at 5 years p = 0.380 p = 0.254 p = 0.064 % p = 1.000

Gamma-1: Five Year Follow-up Among patients treated with gamma brachytherapy or placebo for in-stent restenosis in native coronary lesions, there were no statistically significant differences in MACE, TLR, or TVR at five-years. The risk of recurrent MI tended to be higher among patients treated with gamma brachytherapy (p=0.06) While there was a clinical benefit at 9 months for gamma brachytherapy, these five-year results demonstrate no significant benefit of gamma brahcytherapy consistent with a “late catch-up” or delay in restenosis among these patients.